{"id":53491,"name":"BIOHAVEN PHARMACEUTICALS, INC.","slug":"biohaven-pharmaceuticals-inc","state":"CT","country":"United States of America","description":"A biopharmaceutical company.","totalSpending":730000,"filings":15,"yearlySpending":[{"year":2022,"income":20000},{"year":2023,"income":230000},{"year":2024,"income":240000},{"year":2025,"income":240000}],"issues":[{"code":"HCR","display":"Health Issues"}],"firms":["DLA PIPER LLP (US)"],"lobbyists":["JAMES GREENWOOD","ALEX PINSON","JAMIE GREGORIAN","KARINA LYNCH","VINCENT SARUBBI"],"govEntities":["SENATE","HOUSE OF REPRESENTATIVES","Executive Office of the President (EOP)","Health & Human Services, Dept of (HHS)"],"sampleDescriptions":["Policies, proposals, and FDA regulation of pharmaceuticals in disease areas served by Biohaven.","Policies related to drug approval for treatment of rare diseases. Policies related to exclusivity of small molecule drugs.","Policies, proposals, and FDA regulation of pharmaceuticals in disease areas served by Biohaven.","Policies related to drug approval for treatment of rare diseases. Policies related to exclusivity of small molecule drugs.","Policies related to drug approval for treatment of rare diseases. Policies related to exclusivity of small molecule drugs."]}